Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine With Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer
The purpose of this phase I study is to determine the maximum tolerated dose of the chemotherapy drugs nab-paclitaxel and gemcitabine when combined with hypofractionated ablative proton therapy for the treatment of locally advanced pancreatic cancer.
Study ID: HP-00081403
Trial Phase: Phase I
Trial Sponsor: University of Maryland
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Proton Radiation